We've teamed up with the experts to give you the very best training support and advice for your event.
South Coast Challenge 2017
Got a place already?
Request a sponsorship pack and join our team.
Walk, jog or run across the South Coast and experience the stunning scenery first hand.
Most of the 2,000 challengers taking part will be walking at their own pace, quite a few will jog parts, and some will run the full 100km. However you take it on you'll be supported all the way by our team and rewarded with an overwhelming sense of achievement. Push yourself in 2017 - join us!
Early bird discount: Sign up before 21st October and enjoy 30% off the registration fee. Enjoy 25% off if you sign up between 21st October and 18th November and 20% off for CRUK supporters all year round.
Join our team and choose the distance that best suits you:
100km – Take on the full distance for a registration fee of £56 (normally £70) when you pledge to raise a minimum of £395.
2 day challenge (100 km) - Take on the 100km for £56 with a minimum pledge of £395 - but you can take your time and camp at half way.
50km – Take on the half distance for £40 (normally £50) when you pledge to raise a minimum of £275.
23km - Take on the quarter distance for £32 (normally £50) when you pledge to raise a minimum of £150.
N.B. You will have to raise 50% of your sponsorship target 4 weeks before the event to confirm your place. But don’t worry; we’ve got loads of fundraising tips and support to help you achieve this.
Our supporters fund over half the research done in the UK – together We Will beat cancer sooner.
Race day information
If you join Team CRUK we will support you all the way, we offer training and fundraising tips.
Any questions? Click here to read our most frequently asked questions, which should provide you with all the information you need. Or, you can contact the Sports Team on 0300 123 5461.
For more information, please click here to visit the official website.
Did you know…
Cancer Research UK Completed the first UK trials of a new generation of highly targeted cancer drugs, known as PARP inhibitors, for people with breast and ovarian cancers caused by inherited gene faults.